companies / imubiosciences-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-06-05 json
| total_raised | 53,000,00053.0M | ○ |
|---|---|---|
| founded | null | |
| hq | London | |
| industry | unknown | |
| stage | series-a |
IMU Biosciences runs an HD Immunology platform that analyzes blood samples to map 2,500 immune cell subsets and over 100 million data points in real time. It serves clinical research groups, pharma, biotech, and diagnostics firms. Its edge is the resolution and scale of its immune mapping from just 2 milliliters of blood.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2026-06-01 | series-a | 53,000,00053.0M | null | ○ |
none
| fact | status | src |
|---|---|---|
| Series A, $53.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |